Gedea Biotech
Lund
About Gedea Biotech
Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections. Vaginal yeast infections are a major problem that affects about 75% of all women at some point in life. Gedea Biotech's substance, GA101, is a natural substance that has always been part of their environment. It acts by lowering the pH as well as providing a physical barrier protection and inhibiting biofilm formation. The first product will be a topical treatment of vaginal fungal infections.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.3M
- Last round: Grant (Feb 2024)
- Website: gedeabiotech.com
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/gedea-biotech-156305 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.